Generic Medicine Info
Indications and Dosage
Adult: 2 g daily in divided doses.
Renal Impairment
CrCl (mL/min) Dosage
<10 Avoid.
10-50 Administer every 12-18 hr.
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Severe renal or hepatic impairment; hypoalbuminaemia; primary biliary cirrhosis; gallbladder disease; nephrotic syndrome; pregnancy; lactation.
Special Precautions
Renal impairment; discontinue if myotoxicity is suspected or creatine kinase conc increases significantly. Caution in patients with peptic ulcer.
Adverse Reactions
Anorexia; nausea; gastric discomfort; stomatitis; headache; dizziness; vertigo; fatigue; skin reactions; alopoecia; impotence; anaemia; leucopenia; myotoxicity; thrombocytopenia; vomiting; diarrhoea; dyspepsia; flatulence; wt gain; drowsiness; hepatomegaly. Increased incidence of cholecystitis, gallstones and pancreatitis.
Drug Interactions
May increase anticoagulant effects of acenocoumarol, warfarin and phenindione. Increased risk of muscle toxicity with HMG-CoA reductase inhibitors. May enhance hypoglycaemic effect of antidiabetic drugs. May cause rhabdomyolysis or neuromyopathy when used with colchicine. Risk of rhabdomyolysis with sirolimus. May increase risk of gallstone formation when used with ezetimibe. Clearance may be increased by oral contraceptives. Efficacy may be reduced with rifampicin. Serum levels may be doubled by probenecid.
Lab Interference
Raised serum aminotransferase and creatine phosphokinase concentrations.
Mechanism of Action: Clofibrate reduces elevated concentrations of very low-density lipoproteins and LDL cholesterol and increases conc of high-density lipoprotein cholesterol.
Absorption: Readily absorbed in the GI tract.
Distribution: Clofibric acid: ≥95% bound to plasma proteins.
Metabolism: Rapidly hydrolysed to its active metabolite, chlorophenoxyisobutyric acid (clofibric acid).
Excretion: Elimination half-life (Clofibric acid): 18-22 hr. Excreted in the urine, mainly as glucuronide conjugate.
MIMS Class
Dyslipidaemic Agents
Disclaimer: This information is independently developed by MIMS based on Clofibrate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in